IL-2

100% Secure


Recombinant Human Interleukin-2

Product Type
Recombinant Protein
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
PHP042A E FN WB 10 µg
PHP042 E FN WB 50 µg
Recombinant human interleukin 2 is an Escherichia coli-derived recombinant protein corresponding to full-length mature human interleukin-2, a secreted peptide required for T-cell proliferation. This preparation has an ED50 of 0.1ng/ml as determined by the dose-dependent stimulation of the proliferation of murine CTLL-2 cells.

Product Details

Target Species
Human
Species Cross-Reactivity
Target SpeciesCross Reactivity
Cynomolgus monkey
Rhesus Monkey
Dolphin
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified protein produced in E. coli - lyophilised
Reconstitution
Pack Size: 10 µg
Reconstitute with 0.1ml 0.1M acetic acid
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
Pack Size: 50 µg
Reconstitute with 0.5 ml 0.1M acetic acid. Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
Buffer Solution
10mM Sodium citrate
Preservative Stabilisers
None present
Activity
1 x 107 units/mg
Purity
>98% by SDS PAGE and HPLC analysis
Approx. Protein Concentrations
Pack Size: 10 µg
Total protein concentration 0.1mg/ml after reconstitution.
Pack Size: 50 µg
Total protein concentration 0.1 mg/ml after reconstitution
Protein Molecular Weight
15.4kDa (134 Amino acid sequence)
Endotoxin Level
<0.1 ng/ug

Storage Information

Storage
Pack Size: 10 µg
Prior to reconstitution store at -20oC. Following reconstitution store at -20oC.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
Pack Size: 50 µg
Prior to reconstitution store at +4oC. Following reconstitution store at -20oC.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
3 months from date of reconstitution.

More Information

UniProt
P60568 Related reagents
Entrez Gene
IL2 Related reagents
GO Terms
GO:0002903 negative regulation of B cell apoptosis
GO:0007155 cell adhesion
GO:0005125 cytokine activity
GO:0005134 interleukin-2 receptor binding
GO:0005615 extracellular space
GO:0006916 anti-apoptosis
GO:0006955 immune response
GO:0007267 cell-cell signaling
GO:0008083 growth factor activity
GO:0019209 kinase activator activity
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0030307 positive regulation of cell growth
GO:0030890 positive regulation of B cell proliferation
GO:0032740 positive regulation of interleukin-17 production
GO:0034105 positive regulation of tissue remodeling
GO:0042104 positive regulation of activated T cell proliferation
GO:0042523 positive regulation of tyrosine phosphorylation of Stat5 protein
GO:0050729 positive regulation of inflammatory response
Regulatory
For research purposes only

Applications of IL-2

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 0.2 0.4ng/well
Functional Assays 0.1 Pack Size: 10 µg
0.1ng/ml Pack Size: 50 µg
2.0ng/ml
Western Blotting 1.5 3.0ng/lane
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
ELISA
Recombinant Rat interleukin-2 may be used as a standard for ELISA applications with Rat anti Human IL-2 antibody, clone MQ1-17H12 (MCA1553).
Western Blotting
Recombinant human IL-2 may be used as a positive control for Western Blotting applications using Rabbit anti Human IL-2 antibodies (AAR38) for detection

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Rabbit anti Human Interleukin-2 AHP1032 0.1 mg E FN P* WB
Rabbit anti Human Interleukin-2:Biotin AHP1032B 50 µg E WB

Application Based External Images

Functional Assays

Product Specific References

References for IL-2

  1. Akari, H. et al. (2000) Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.
    J. Virol. 74 (6): 2907 - 2912.
  2. Chan, P.K. et al. (2010) T-cell response to human papillomavirus type 58 L1, E6 and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia and invasive cancer.
    Clin Vaccine Immunol. 17: 1315-21.
  3. Doi, N. et al. (2010) Growth ability in various macaque cell lines of HIV-1 with simian cell-tropism.
    J Med Invest. 57: 284-92.
  4. Vaughan, K. et al. (2007) A DNA vaccine against dolphin morbillivirus is immunogenic in bottlenose dolphins.
    Vet Immunol Immunopathol. 120: 260-6.
  5. Ban, S.A. et al. (2014) Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3.
    J Clin Immunol. 34 (8): 941-53.
  6. Geoghegan, V. et al. (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling.
    Nat Commun. 6: 6758.
  7. Yutani, S. et al. (2017) Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
    Cancer Sci. 108 (9): 1732-8.